The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
Intermolecular Amination of Unactivated C(sp<sup>3</sup>
)−H Bonds with Cyclic Alkylamines: Formation of C(sp<sup>3</sup>
)−N Bonds through Copper/Oxygen-Mediated C(sp<sup>3</sup>
)−H/N−H Activation
作者:Quan Gou、Yu-Wen Yang、Zi-Ning Liu、Jun Qin
DOI:10.1002/chem.201603370
日期:2016.11.2
unactivated C(sp3)−H bonds by cyclic alkylamines mediated by Cu(OAc)2/O2 is reported. This method avoids the use of benzoyloxyamines as the aminating reagent, which are normally prepared from alkylamines in extra steps. A variety of unnatural β2, 2‐amino acid analogues are synthesized by this simple and efficient procedure. This approach offers a solution to the previous unmet challenge of C(sp3)−H/N−H
报道了由Cu(OAc)2 / O 2介导的环状烷基胺对未活化的C(sp 3)-H键进行分子间胺化的第一个例子。该方法避免了使用苯甲酰氧基胺作为胺化试剂,该苯甲酰氧基胺通常是在额外的步骤中由烷基胺制备的。多种非天然β的2,2 -氨基酸类似物是通过这种简单且有效的方法进行合成。这种方法为C(sp 3)-H / N-H活化形成C(sp 3)-N键的先前未解决的挑战提供了解决方案。
AMINOTHIAZOLES AND THEIR USES
申请人:Bushell Simon
公开号:US20140315790A1
公开(公告)日:2014-10-23
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
MACROCYCLES AND THEIR USES
申请人:Fujimoto Roger Aki
公开号:US20090186830A1
公开(公告)日:2009-07-23
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
Phenol esters
申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
公开号:EP0307115A1
公开(公告)日:1989-03-15
A phenol ester of xamoterol of the formula:
wherein X is a methylene radical or a direct bond,
R¹ is a hydrogen atom or an alkyl or alkenyl radical of 3 to 8 carbon atoms, and
R² and R³, which may be the same or different, are each a 1-4C alkyl radical;
provided that
(i) when X is a direct bond, either R¹ is a hydrogen atom and R² and R³ are each a 2-4C alkyl radical, or R¹ is a 3-8C alkyl or alkenyl radical and R² and R³ are each a methyl radical; or
(ii) when X is a methylene radical, R¹ is an allyl radical or a 5-7C alkyl radical, and R² and R³ are each a methyl radical; and the pharmaceutically acceptable acid addition salts thereof.